TY - JOUR
T1 - Recent HIV-1 infection in Israel 2017–2021
T2 - Evaluation of geenius and HIV-1/2 combo assays for identifying recent infection detected by Sedia assay and assessment of factors related to recent infection: Recent HIV-1 infection in Israel
AU - Azuri, Eyal
AU - Wax, Marina
AU - Gozlan, Yael
AU - Wagner, Tali
AU - Mor, Orna
N1 - Publisher Copyright:
© 2023 Elsevier B.V.
PY - 2024/2
Y1 - 2024/2
N2 - Background: Estimating HIV-1 recency of infection for incidence and local outbreaks detection usually involves specifically designed assays. Here, we established an approach to identify recent infections, estimate their rate, and assess potential risk factors. Methods: Randomly selected HIV-1 positive samples (n = 382) collected in 2017–2021 were tested by Sedia and compared to the results of Geenius recency algorithm and the S/CO values of the HIV-1/2 Combo assay. Using Geenius and Combo recency verdict, we assessed all cases diagnosed in 2017–2021. Related factors were further assessed. Results: While Geenius and Combo had a sensitivity of 65.9 % and 89.30 %, respectively, and specificity of 96 % and 90 %, respectively, compared to Sedia, higher concordance (97.2 %) and kappa (>0.9) were observed when the verdict of both assays together was compared to Sedia. Using this approach, 15.3 % (238/1548) of individuals diagnosed in 2017–2021 were defined as recently infected. In multivariate analysis, recent diagnosis was mainly associated with men who have sex with men (MSM) and with birthplace in Israel, Western/Central Europe, or North America. Conclusions: Only 15.3 % of infections in 2017–2021, mainly in MSM and Israeli/Western countries-born individuals, were diagnosed early. Regular diagnostic assays have a potential to identify and monitor trends in recent infections.
AB - Background: Estimating HIV-1 recency of infection for incidence and local outbreaks detection usually involves specifically designed assays. Here, we established an approach to identify recent infections, estimate their rate, and assess potential risk factors. Methods: Randomly selected HIV-1 positive samples (n = 382) collected in 2017–2021 were tested by Sedia and compared to the results of Geenius recency algorithm and the S/CO values of the HIV-1/2 Combo assay. Using Geenius and Combo recency verdict, we assessed all cases diagnosed in 2017–2021. Related factors were further assessed. Results: While Geenius and Combo had a sensitivity of 65.9 % and 89.30 %, respectively, and specificity of 96 % and 90 %, respectively, compared to Sedia, higher concordance (97.2 %) and kappa (>0.9) were observed when the verdict of both assays together was compared to Sedia. Using this approach, 15.3 % (238/1548) of individuals diagnosed in 2017–2021 were defined as recently infected. In multivariate analysis, recent diagnosis was mainly associated with men who have sex with men (MSM) and with birthplace in Israel, Western/Central Europe, or North America. Conclusions: Only 15.3 % of infections in 2017–2021, mainly in MSM and Israeli/Western countries-born individuals, were diagnosed early. Regular diagnostic assays have a potential to identify and monitor trends in recent infections.
KW - Combo
KW - Geenius
KW - Hiv-1
KW - Recency of infection
KW - Sedia
UR - http://www.scopus.com/inward/record.url?scp=85180591358&partnerID=8YFLogxK
U2 - 10.1016/j.jcv.2023.105624
DO - 10.1016/j.jcv.2023.105624
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 38118239
AN - SCOPUS:85180591358
SN - 1386-6532
VL - 170
JO - Journal of Clinical Virology
JF - Journal of Clinical Virology
M1 - 105624
ER -